Regenerative medicine company CollPlant said today it received agrant from the Israel Innovation Authority to help support its plant-based rhCollagen technology for tissue repairs. The grant will specifically support uses of its rhCollagen-based formulations intended for use as BioInk for 3D printing tissues and organs, the company said. The total budget for the program $1.2 million (NIS […]
CollPlant raises $5m in private placement
Regenerative medicine company CollPlant said today it inked a $5 million private placement deal to support its plant-based rhCollagen technology for tissue repairs. As part of the private placement round, Israel-based CollPlant said it will pursue an up-listing of its ADSs on the Nasdaq exchange following the 1st phase of the transaction closing, which is slated […]
New CollPlant division focuses on 3D bioprinting
Regenerative medicine company CollPlant said Thursday that it has created a new division to focus on collagen-based bioprinting. CollPlant has been utilizing its proprietary plant-based rhCollagen technology for tissue repair. The new division will further develop collagen-based bioink for use in 3D printers creating organs and tissues. The Ness Ziona, Israel–based company says it has 3D […]
7 medtech stories we missed this week: April 14, 2017
From FDA approvals to business expansion plans, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. BioTelemetry launches offer to acquire LifeWatch BioTelemetry and LifeWatch announced in an April 9 press release that the 2 companies have entered a transaction agreement that states BioTelemetry will launch a tender offer […]
CollPlant files for $25 million IPO
Regenerative medicine company CollPlant today released information on its planned initial public offering, looking to bring in $25 million. CollPlant produces wound care and regenerative devices based on plant-derived collagen. Their products include the Vergenix FG flowable gel intended to treat chronic and acute wounds. The wound-filling gel utilizes Israel-based CollPlant’s proprietary tobacco plant-based technology, […]
CollPlant jumps on CE Mark win for wound filler
CollPlant said today it won CE Mark approval in the European Union for its Vergenix FG flowable gel intended to treat chronic and acute wounds. In response to the news, the company’s share price was up 4.62% on the Tel Aviv Stock Exchange at midday. The wound-filling gel utilizes Israel-based CollPlant’s proprietary tobacco plant-based technology […]
